Based on Globocan 2012 data, the incidence of Hodgkin lymphoma (HL) among Indian males was 5,677 per 100,000 and 2,938 per 100,000 in Indian females. In terms of mortality for HL, 2,938 males per 100,000 died and 1,404 per 100,000 females died. With non-Hodgkin lymphoma (NHL), the incidence among Indian males was 15,884 per 100,000 and 7,918 per 100,000 among Indian females. The rate of mortality among males for NHL was 11,071 per 100,000 and 5,526 per 100,000 for females. Non-Hodgkin lymphoma, is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues.
Researchers want to collect information from the scans and create a database so that they can see how patients' individual biological differences affect how well particular treatments work for them. Doctors hope they will be able to use this information in the future to choose the most appropriate treatment for patients. This trial is no longer recruiting patients and we are waiting for the results. Laboratory studies in a patient with suspected NHL should include the following:
• HIV serology: Especially in patients with diffuse large cell immunoblastic or small non cleaved histologies
• Human T-cell lymphotropic virus-1 serology: For patients with adult T-cell leukemia/lymphoma
• Hepatitis B testing: In patients in whom rituximab therapy is planned because reactivation has been reported